PMID: 2495012Jan 1, 1989Paper

Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514)

Atherosclerosis
G YoshinoS Baba

Abstract

We examined the long-term effect of pravastatin, a new potent inhibitor of endogenous cholesterol biosynthesis, on glucose and lipid metabolism in hyperlipidemic NIDDM. Ten patients (5 on sulfonylurea, 5 on diet) were studied over 12 months. Five were WHO type IIa and 5 were type IIb. Blood was taken before and then 1, 6 and 12 months after initiating 10 or 20 mg daily of pravastatin. The cholesterol concentration in whole plasma and very low density lipoprotein (VLDL), plasma triglyceride and apolipoprotein (apo) B were all significantly decreased within the first month. These changes lasted for 1 year. High density lipoprotein (HDL)-cholesterol increased in the first month but returned to base line thereafter. Low density lipoprotein (LDL)-cholesterol tended to decrease in the first month, and was suppressed significantly from the 6th month (11%) to the 12th month (16%). The effect of pravastatin on LDL-cholesterol in NIDDM was slower and weaker than that published for non-diabetic hypercholesterolemia. Therefore, the mechanism by which pravastatin suppresses plasma cholesterol levels in these two conditions may differ. After 1 year, no adverse effects were noted on hematopoietic, hepatic or renal function. Blood glucose leve...Continue Reading

References

Aug 19, 1976·The New England Journal of Medicine·R J KoenigA Cerami
Sep 1, 1986·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·T KazumiS Baba
Jun 12, 1987·JAMA : the Journal of the American Medical Association·N NakayaY Goto
Oct 1, 1987·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·G YoshinoM Otsuki
Jan 14, 1988·The New England Journal of Medicine·A Garg, S M Grundy
Aug 1, 1986·Metabolism: Clinical and Experimental·S IshibashiF Takaku
Jan 1, 1973·Nutrition and Metabolism·A K Khachadurian, S M Uthman
Sep 1, 1965·Immunochemistry·G ManciniJ F Heremans
Jan 1, 1971·Annals of Internal Medicine·W B KannelP M McNamara
May 8, 1981·Science·M S BrownJ L Goldstein
Feb 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·P T KovanenM S Brown
Mar 1, 1983·The Journal of Clinical Investigation·A H KissebahP W Adams
Jul 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·D W BilheimerJ L Goldstein
Mar 20, 1980·The New England Journal of Medicine·J M SosenkoK H Gabbay
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON
Mar 1, 1955·The American Journal of Medicine·I M LIEBOWB MILLER

❮ Previous
Next ❯

Citations

Feb 1, 1990·Diabetes/metabolism Reviews·F L Dunn
Apr 1, 1992·European Journal of Drug Metabolism and Pharmacokinetics·T KomaiM Tanaka
Jun 1, 1996·Diabetes Research and Clinical Practice·G YoshinoT Kazumi
Apr 15, 1991·Biochimica Et Biophysica Acta·C M Arbeeny, K E Bergquist
Dec 1, 1990·Baillière's Clinical Endocrinology and Metabolism·M R Taskinen
Oct 1, 1991·Postgraduate Medical Journal·P N Durrington
Apr 1, 1991·DICP : the Annals of Pharmacotherapy·R H Raasch
Dec 4, 2003·Drugs & Aging·Lynne M Bang, Karen L Goa
Sep 1, 1992·Current Problems in Cardiology·J S Prihoda, D R Illingworth

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.